优化剖宫产术后阿片类药物处方数量:一项随机对照试验
在这项多中心随机对照非劣效性试验中,个体化阿片类药物处方方案(IOPP)联合共享决策与固定数量(20片5 mg羟考酮)相比,剖宫产术后出院1周中度至重度疼痛发生率分别为59.5%和60.1%,风险差0.67%(95%CI -2.03%至3.37%),达到非劣效;IOPP组出院时收到的片数中位数更少(14片 vs 20片,P<.001)。
要点
- IOPP联合共享决策在剖宫产术后出院1周疼痛管理上非劣效于固定20片羟考酮。
- IOPP组出院时收到的阿片类药物片数中位数为14片,少于固定组的20片(P<.001)。
- 该方案基于出院前24小时阿片类药物使用量计算推荐片数,患者经教育后选择最多20片。
核心结论
- 与固定数量相比,IOPP联合共享决策在剖宫产术后出院1周门诊镇痛方面非劣效,且出院时开具的阿片类药物片数更少。
研究设计与样本
- 多中心随机对照非劣效性试验,在31个参与Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network的中心招募,计划样本量5,500例,实际纳入5,521例(IOPP组2,748例,固定数量组2,773例),随访至出院后12周。
主要发现
- 主要结局出院后1周BPI(Brief Pain Inventory)中度至重度疼痛(评分≥4分,可能范围0-10)发生率:IOPP组59.5% vs 固定数量组60.1%,风险差0.67%(95%CI -2.03%至3.37%),非劣效界值-5.0。
- 至产后90天,IOPP组收到的片数中位数为14片(四分位距4-20),固定数量组为20片,P<.001。
关键数值与推荐
- IOPP组根据出院前24小时阿片类药物使用量计算推荐片数,经教育模块和共享决策后,参与者选择出院片数(最多20片)。
- 固定数量组出院时给予20片5 mg羟考酮。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether an individualized opioid-prescription protocol (IOPP) with a shared decision-making component can be used without compromising postcesarean pain management. METHODS: In this multicenter randomized controlled noninferiority trial, we compared IOPP with shared decision making with a fixed quantity of opioid tablets at hospital discharge. We recruited at 31 centers participating in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Study participants had uncomplicated cesarean births. Follow-up occurred through 12 weeks postdischarge. Individuals with complicated cesarean births or history of opioid use in the pregnancy were excluded. Participants were randomized 1:1 to IOPP with shared decision making or fixed quantity (20 tablets of 5 mg oxycodone). In the IOPP group, we calculated recommended tablet quantity based on opioid use in the 24 hours before discharge. After an educational module and shared decision making, participants selected a quantity of discharge tablets (up to 20). The primary outcome was moderate to severe pain (score 4 or higher [possible range 0-10]) on the BPI (Brief Pain Inventory) at 1 week after discharge. A total sample size of 5,500 participants was planned to assess whether IOPP with shared decision making was not inferior to the fixed quantity of 20 tablets. RESULTS: From September 2020 to March 2022, 18,990 individuals were screened and 5,521 were enrolled (n=2,748 IOPP group, n=2,773 fixed-quantity group). For the primary outcome, IOPP with shared decision making was not inferior to fixed quantity (59.5% vs 60.1%, risk difference 0.67%; 95% CI, -2.03% to 3.37%, noninferiority margin -5.0) and resulted in significantly fewer tablets received (median 14 [interquartile range 4-20] vs 20, P <.001) through 90 days postpartum. CONCLUSION: Compared with fixed quantity, IOPP with shared decision making was noninferior for outpatient postcesarean analgesia at 1 week postdischarge and resulted in fewer prescribed opioid tablets at discharge. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04296396.
引用
- Smid MC, Clifton RG, Rood K, et al. Optimizing Opioid Prescription Quantity After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2024. PMID: 38857509. doi:10.1097/AOG.0000000000005649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。